Business Context and Reporting Period
This Form 8-K Current Report was filed by DiaMedica Therapeutics Inc. on March 6, 2025, regarding events occurring on February 28, 2025. The Company is a late-stage biopharmaceutical firm incorporated in British Columbia, with its principal executive offices in Minneapolis, Minnesota. Its voting common shares trade on The Nasdaq Stock Market LLC under the symbol DMAC.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the departure of a long-serving director:
- Richard Pilnik, a Board member for over 15 years and former Chairman of the Board (serving in that role for over a decade), has retired and will not stand for re-election at the 2025 Annual General Meeting (AGM).
- His term as a director will expire upon the conclusion of the AGM, scheduled for May 15, 2025.
- The departure is not due to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Management Commentary
Succession Planning: The Board has already transitioned the Chairman of the Board role from Mr. Pilnik to James Parsons (who joined the Board in 2015 and chairs the Audit Committee). Additionally, Daniel J. O'Connor was recently appointed as a new director.
Committee Restructuring: The Board intends to re-evaluate the composition of its committees, including chair roles, to ensure a seamless transition following Mr. Pilnik's departure.
Management Commentary: Rick Pauls, President and CEO, stated the Company is grateful for Mr. Pilnik's service, specifically recognizing his contributions during the Company's transition to a late-stage biopharmaceutical company.
Investor Verification Checklist
- Verify the date of the 2025 Annual General Meeting (AGM) is May 15, 2025.
- Confirm the new composition of the Board committees following the AGM.
- Review the Company's most recent 10-K or 10-Q for financial data, as this 8-K contains no financial metrics.
- Monitor future filings for the official appointment of a new Chair for the Nominating and Corporate Governance Committee.